How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?

被引：5
|
作者：
Christoph Koenen
机构：
[1] Novo Nordisk A/S,
[2] Krogshøjvej 55,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷 / 10期
关键词：
D O I：
10.1038/ncpendmet0972
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：E1 / E1
相关论文
共 50 条
  • [41] Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain
    Rosenstock, Julio
    Davies, Melanie
    Home, Philip D.
    Larsen, Jens
    Tamer, Soren C.
    Schernthaner, Guntram
    DIABETES, 2006, 55 : A132 - A132
  • [42] Willingness to start insulin therapy among insulin-naïve persons with type 2 diabetes mellitus at Gulu Regional Referral Hospital, Gulu City, Uganda
    Nakitto, Brenda
    Opedo, Moses
    Nansubuga, Federes
    Omondi, Edward
    Musinguzi, Emmanuel
    Otile, Edwin Cleopas
    Ekak, Steven
    Nannungi, Christine
    Apiyo, Paska
    Pebolo, Pebalo Francis
    Bongomin, Felix
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2024, 15
  • [43] The relative cost effectiveness of insulin glargine versus detemir insulin using UK real life data in patients with type 2 diabetes mellitus
    Tetlow, A. P.
    McEwan, P.
    Gordon, J.
    DIABETOLOGIA, 2008, 51 : S406 - S406
  • [44] Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes
    Vos, Rimke C.
    Rutten, Guy E. H. M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (15): : 1489 - 1490
  • [45] Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
    Eun-Gyoung Hong
    Kyung-Wan Min
    Jung Soo Lim
    Kyu-Jeung Ahn
    Chul Woo Ahn
    Jae-Myung Yu
    Hye Soon Kim
    Hyun Jin Kim
    Won Kim
    Dong Han Kim
    Hak Chul Jang
    Advances in Therapy, 2024, 41 : 1967 - 1982
  • [46] Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes -: a simulation with the Diabetes Mellitus Model (DMM)
    Janka, H. U.
    Hessel, F.
    Walzer, S.
    Mueller, E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (12) : 623 - 630
  • [47] COST COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN TYPE 2 DIABETES MELLITUS IN ARGENTINA: ATRIAL-BASED PROBABILISTIC MODEL
    Pichon-Riviere, A.
    Caporale, J. E.
    Augustovski, F. A.
    von Schulz-Hausmann, C.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2008, 11 (06) : A506 - A506
  • [48] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [49] Insulin Glargine versus Insulin Detemir: Glycemic Control and Insulin Dose in Type 2 Diabetes Mellitus Patients Using a Medical Record Linkage System in the Netherlands
    Eland, Ingo A.
    Heintjes, Edith M.
    Houweling, Leanne
    degrooth, Ricardo
    Veneman, Thiemo F.
    Bouter, K. Paul
    JOURNAL OF DIABETES & METABOLISM, 2011, 2 (09)
  • [50] GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE OR DETEMIR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS-AN ANALYSIS OF ELECTRONIC MEDICAL RECORDS
    Levin, P.
    Danel, A.
    Bromberger, L.
    Choi, J. C.
    Mersey, J.
    VALUE IN HEALTH, 2008, 11 (06) : A496 - A497
12345